Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Prostate Adenocarcinoma: early-phase trial registry
2 of 3 indexed Recurrent Prostate Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Recurrent Prostate Adenocarcinoma: 3 US clinical trials tracked, 2 recruiting.
Recurrent Prostate Adenocarcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-prostate-adenocarcinoma
OPEN 2 | RECR 67% | LATE 1 | EARLY 2 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Recurrent Prostate Adenocarcinoma lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Prostate Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Prostate Adenocarcinoma is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
NCT06205316
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT07150715
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Jonsson Comprehensive Cancer Center
NCT05496959
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Prostate Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Prostate Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Prostate Adenocarcinoma page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Recurrent Prostate Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Recurrent Prostate Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Prostate Adenocarcinoma condition card totals 3 registered trials; most-linked intervention Stereotactic Body Radiation Therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.